H2o Therapeutics
H2o Therapeutics is a privately held digital therapeutics company that develops FDA-cleared and EU MDR-certified prescription mobile apps, primarily Parky — an Apple Watch-based Parkinson's disease symptom monitoring application — serving patients, neurologists, and federal healthcare systems.
- Company typePrivate
- Founded2017
- HeadquartersÇankaya
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What H2o Therapeutics does
H2o Therapeutics is a privately held, founder-led digital therapeutics company founded in 2014 (some sources cite 2017) and headquartered in Çankaya, Ankara, Turkey, with a US office in Fairfax, Virginia. The company develops prescription digital therapeutics and software-as-a-medical-device (SaMD) solutions targeting neurological and chronic conditions, with Parkinson's disease as its primary therapeutic focus. Its flagship product, Parky, is an Apple Watch-based prescription mobile app that uses Apple's Movement Disorder API to passively monitor motor symptoms — tremors, dyskinesia, steps, and sleep — and generates daily, weekly, and monthly symptom reports correlating motor activity with medication adherence. Parky received FDA 510(k) marketing clearance in November 2022 and EU MDR Class IIa certification in June 2025, positioning it among the few internationally regulated mobile medical apps specifically developed for Parkinson's disease. The company operates under ISO 13485:2016 quality management certification and adheres to IEC 62304:2006 and ISO 14971:2019 standards, with HIPAA and GDPR compliance in place across its US and EU operations.
The platform extends beyond Parky to include the Parky Provider Portal — a web-based interface through which healthcare professionals review patient symptom data, issue prescriptions, and conduct remote monitoring — and a pipeline of two additional digital therapeutics with FDA submissions planned. H2o Therapeutics also offers end-to-to-end digital health development services for partners seeking FDA- and MDR-regulated DTx and SaMD products. The company generates revenue primarily through prescription-based distribution of Parky via healthcare providers and federal procurement channels, with the app listed on the VA Federal Supply Schedule (FSS) and GSA Advantage through its SDVOSB channel partner Lovell Government Services, and broader US commercialization supported by AmerisourceBergen. Founded by Yagmur Selin Gulmus, H2o Therapeutics is explicitly described as woman-founded and non-VC-backed, operating as a small, multi-disciplinary team covering design, development, regulatory, medical, and commercial functions across its Turkish and US offices.
H2o Therapeutics firmographics
Firmographics- Name
- H2o Therapeutics
- Legal name
- H2O Therapeutics Co.
- Website
- https://h2otherapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- H2o Therapeutics is a privately held digital therapeutics company that develops FDA-cleared and EU MDR-certified prescription mobile apps, primarily Parky — an Apple Watch-based Parkinson's disease symptom monitoring application — serving patients, neurologists, and federal healthcare systems.
- Ownership category
- akta.pro rank
H2o Therapeutics industry classification
Industry- Product category
- Digital Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Prescription Digital Therapeutics (PDT) (HLACANAB)
- akta.pro secondary industries
- Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where H2o Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Çankaya
Offices2 records
Markets served
H2o Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Prescription Digital Therapeutics: Parky is a prescription mobile app that generates revenue through healthcare provider prescriptions. The app monitors Parkinson's disease symptoms via Apple Watch and delivers reports correlating motor symptoms with medication adherence.
- Digital Health Solutions Development: Provides end-to-end digital health development services for partners, including regulatory-ready DTx and SaMD solutions for FDA and MDR-regulated markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Prescription-based digital therapeutic - pricing determined through healthcare system procurement |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
H2o Therapeutics product offering
Product offeringCore offering
H2o Therapeutics develops regulatory-ready digital therapeutics and Software as a Medical Device (SaMD) solutions, with its flagship product Parky being an FDA-cleared and EU MDR Class IIa-certified prescription mobile app that uses Apple Watch sensors and Apple's Movement Disorder API to continuously monitor Parkinson's Disease motor symptoms (tremors, dyskinesia) and correlate them with medication adherence. The company also offers the Parky Provider Portal for clinicians and provides end-to-end digital health development services for partners in FDA and MDR-regulated markets.
Product overview
H2o Therapeutics is a digital health company offering turnkey, regulatory-ready digital health solutions with a focus on wearable-integrated software for neurological and chronic conditions. The flagship product is Parky, an FDA-cleared and EU MDR Class IIa certified Apple Watch-based symptom monitoring app for Parkinson's Disease. The company provides comprehensive digital health development services including user-centric mobile applications for Apple devices, seamless API integration with healthcare systems, and full-service development from ideation through commercialization. The product ecosystem includes Parky (core symptom monitoring app), the Parky Provider Portal (healthcare professional interface), and pipeline digital therapeutics products targeting other chronic conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Parky: FDA-cleared, EU MDR-certified Apple Watch-based mobile app for monitoring and managing Parkinson's Disease symptoms, including tremor and dyskinesia, with medication reminders and symptom report generation.
Products and services
- Parky FDA-cleared and EU MDR Class IIa-certified prescription mobile app for Apple Watch that monitors and manages Parkinson's Disease symptoms (tremors, dyskinesia, steps, sleep) in real-time. Provides medication reminders, activity tracking, and generates daily, weekly, and monthly symptom reports correlating motor symptoms with medication adherence for sharing with healthcare professionals.
- Parky Provider Portal Web-based portal for healthcare providers (neurologists and movement disorder specialists) to access patient symptom data, create Parky prescriptions, conduct remote monitoring, and manage care for Parkinson's Disease patients using data collected by the Parky app.
- Digital Health Development Services End-to-end digital health development services for pharmaceutical, healthcare, and medical device partners, including user-centric mobile applications for Apple devices, seamless API integration with healthcare systems, and full-service development from ideation through commercialization for regulatory-ready DTx and SaMD solutions in FDA and MDR-regulated markets.
Quantifiable outcome
- Validated in study of 343 participants with 225 monitored for up to 6 months
- +2 more outcomes
Companies that use H2o Therapeutics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
H2o Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature4 records
H2o Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AmerisourceBergencoreCollaboration with AmerisourceBergen to support the commercialization of Apple Watch-Based App Parky for Parkinson's Disease. Leverages AmerisourceBergen's healthcare distribution network for broader market access.
- Lovell Government ServicescoreLovell Government Services serves as h2o Therapeutics' Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve federal healthcare customers including Veterans Health Administration (VHA), Military Health System (MHS), and Indian Health Service (IHS). Parky is available on VA Federal Supply Schedule (FSS) and GSA Advantage, with Lovell streamlining acquisition and helping government agencies fulfill SDVOSB procurement goals.
- Apple Inc.coreIntegration with Apple's Movement Disorder API for Parkinson's symptom tracking via Apple Watch. The API was validated in a 343-participant study referencing the MDS-UPDRS clinical scale, published in Science Translational Medicine.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
H2o Therapeutics competitors and assessment
Company assessmentDirect peers
- Rune Labs: Rune Labs offers StrivePD, a Parkinson's disease management platform using Apple Watch and wearable sensors for motor symptom tracking. Most directly comparable peer given shared Apple Watch-based Parkinson's monitoring focus.
- Akili Interactive: Public prescription digital therapeutics company (EndeavorRx) targeting cognitive and neurological conditions. Comparable as an FDA-cleared, prescription-based digital therapeutic company navigating similar regulatory and reimbursement dynamics.
- Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across neurological and chronic conditions. Comparable business model of prescription DTx with FDA pathway and pharma partnerships.
- Better Therapeutics: Digital therapeutics company developing FDA-regulated prescription software for chronic cardiometabolic conditions. Comparable regulatory and prescription-based DTx model, though targeting different therapeutic areas.
Broad incumbents
- Pear Therapeutics (legacy/Beacon): Historically the leading prescription digital therapeutics company (reSET, reSET-O); assets now under different stewardship. Relevant as a comparable benchmark for the prescription DTx commercialization and reimbursement model.
- WellDoc: Pioneer in chronic-condition digital health (BlueStar for diabetes) with FDA clearance and reimbursement infrastructure. Comparable as an established DTx company building clinician-facing, evidence-based digital therapies for chronic conditions.
- Omada Health: Large-scale virtual care and digital therapeutics company for chronic conditions (diabetes, hypertension, MSK). Comparable as a regulated, evidence-driven digital health company selling to payers, employers, and providers.
Emerging players
- BigHealth: Digital therapeutics company with FDA-cleared products for insomnia (Sleepio) and anxiety. Comparable as a regulated DTx company with prescription/OTC digital therapeutic pathway into chronic conditions.
- Roche/mySugr: mySugr (Roche) provides app-based chronic-condition management for diabetes with regulatory clearances. Comparable as an app-delivered, regulated digital therapeutic for chronic disease sold through healthcare channels.
- Limbic: Digital mental health therapeutic platform with CE-marked software. Comparable as an EU-based digital therapeutic company navigating MDR regulatory pathways and clinical adoption.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
H2o Therapeutics social profiles
Digital presenceH2o Therapeutics compliance and trust
Trust signalCompliance7 records
H2o Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
H2o Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
H2o Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
H2o Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about H2o Therapeutics
What does H2o Therapeutics do?
H2o Therapeutics develops regulatory-ready digital therapeutics and Software as a Medical Device (SaMD) solutions, with its flagship product Parky being an FDA-cleared and EU MDR Class IIa-certified prescription mobile app that uses Apple Watch sensors and Apple's Movement Disorder API to continuously monitor Parkinson's Disease motor symptoms (tremors, dyskinesia) and correlate them with medication adherence. The company also offers the Parky Provider Portal for clinicians and provides end-to-end digital health development services for partners in FDA and MDR-regulated markets.
Is H2o Therapeutics a public or private company?
H2o Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was H2o Therapeutics founded?
H2o Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is H2o Therapeutics based?
H2o Therapeutics is headquartered in Çankaya.
How does H2o Therapeutics make money?
Two revenue lines are on record. Prescription Digital Therapeutics are the primary driver. The others are digital Health Solutions Development.
Who are H2o Therapeutics's main competitors?
Direct peers on record are Rune Labs, Akili Interactive, Click Therapeutics and Better Therapeutics. Broad incumbents are Pear Therapeutics (legacy/Beacon), WellDoc and Omada Health. Emerging players are BigHealth, Roche/mySugr and Limbic.
Does H2o Therapeutics have an API?
No public API is recorded for H2o Therapeutics.
What industry is H2o Therapeutics in?
H2o Therapeutics's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAB, Prescription Digital Therapeutics (PDT), with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 5417 and its SIC code is 8000.